Spotlight On... Massachusetts AG threatens legal action against Gilead over pricey hep C meds; U.K. cost watchdogs green-light cancer meds from AZ, Bayer, Astellas and Novartis but shoot down Lilly's; and more...

Gilead Sciences ($GILD) faces legal action in Massachusetts if it doesn't cut the prices of its hepatitis C drugs. State Attorney General Maura Healey warned CEO John Martin that the cost of Sovaldi and Harvoni--with list prices of $84,000 and $94,500--could violate Massachusetts laws against unfair trade practices. More from FiercePharma

> U.K. cost watchdogs have given a final thumbs-up to AstraZeneca's ($AZN) Lynparza, Bayer's Xofigo, Astellas' Xtandi and Novartis' ($NVS) Farydak. Report

>  The U.K.'s National Institute of Health and Care Excellence (NICE) remains unconvinced that Eli Lilly's ($LLY) stomach cancer med Cyramza is worth its price. Report

> According to J&J ($JNJ) CEO Alex Gorsky, the healthcare industry's investment in patient support programs and other value-added services is still in the "early innings." Report

> Cost regulators in the U.K. have approved routine use of Boehringer Ingelheim's Ofev as a treatment for some patients with idiopathic pulmonary fibrosis (IPF). Report

And Finally... A government-appointed health panel is calling for depression screenings during and after pregnancy. Report (sub. req.)


Suggested Articles

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.

There’s an emerging trend within the SMA community to pair treatments up in the hope that they may provide even better outcomes, one analyst notes.